As part of our Advocacy efforts to draw attention to the problem of Gadolinium retention and the effects of Gadolinium Toxicity, we have conducted our own research.
New Research in 2020
On August 25, 2020, an Open Letter about the Symptoms of Gadolinium Toxicity was sent to the FDA, and Radiologists and Researchers we have communicated with. The title is Symptoms of Gadolinium Toxicity: Can their cause be explained? and it cites many facts from the literature related to gadolinium retention from Gadolinium-based Contrast Agents (GBCAs) and its effects at a cellular level. Based on the literature, it appears that retained gadolinium can affect the function of cells, especially nerve cells, which could trigger a cascade of adverse events that can cause various symptoms.
New Research in 2018
On December 5, 2018, we released our fifth research paper on gadolinium retention from Gadolinium-based Contrast Agents (GBCAs) administered for contrast-enhanced MRIs. The paper is titled Gadolinium Clearance Times for 135 Contrast MRI Cases and includes the contrast agents for the unconfounded cases.
Drawing on the contrast MRI history and 24-hour gadolinium urine testing results that have been received from members of the MRI-Gadolinium-Toxicity Support Group, the study reports retrospectively on 135 cases with 218 urine test results, including 63 unconfounded cases with 81 test results. The participants all had normal kidney function and report having symptoms of gadolinium toxicity. The results reported are dramatic and involve all linear and macrocyclic GBCAs currently in use in the United States.
New Research in 2017
Our paper titled Gadolinium Retention from Contrast MRIs in 70 Cases with Normal Renal Function – 24-hour Urine Test Results, released in February 2017, presents what we believe to be the most comprehensive reporting of retained gadolinium as evidenced by gadolinium concentration in 24-hour urine collections. The 120 test results demonstrate that, contrary to what GBCA product labeling indicates should occur, the gadolinium in our study group did not clear the body within a few days. This finding conflicts with what most practitioners believe will happen. Comparison of results based on the number of contrast MRIs received indicates that cases with higher numbers of contrast administrations have higher levels of chronic toxicity than cases with smaller numbers of contrast administrations. (February 27, 2017)
An Overview of Gadolinium Toxicity is a literature review of over 100 medical and scientific papers that contain information related to the toxicity of retained Gadolinium from Gadolinium-based Contrast Agents. It can be shared with medical professionals to help them understand that all patients are at risk of developing varying degrees of Gadolinium Toxicity as a result of contrast-enhanced MRIs and MRAs. (March 27, 2013)
The Group Self-Study of Gadolinium Retention from Contrast MRIs reports on the toxic levels of Gadolinium found in the urine of 13 participants. This is the first study of this information that has ever been released. All the participants had normal kidney function at the time of their contrast procedures. (October 1, 2013)
The Survey of the Chronic Effects of Retained Gadolinium from Contrast MRIs reports on the symptoms experienced by a group of patients with elevated levels of Gadolinium in their urine and updates the Gadolinium Retention information published in the second paper. The results show high levels of commonality in the participants’ chronic symptoms of Gadolinium Toxicity that are consistent with what is known about NFD/NSF patients’ symptoms and affected body systems. (April 2, 2014)